Zoledronic acid Hospira 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0045 
Minor change in labelling or package leaflet not 
01/10/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/3149/
Periodic Safety Update EU Single assessment - 
09/04/2021 
n/a 
PRAC Recommendation - maintenance 
202008 
zoledronic acid (indicated for cancer and fractures) 
IA/0044 
A.7 - Administrative change - Deletion of 
12/02/2021 
Annex II and 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturing sites 
PL 
IB/0042/G 
This was an application for a group of variations. 
28/09/2020 
22/10/2020 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0041/G 
This was an application for a group of variations. 
27/08/2020 
n/a 
A.4 - Administrative change - Change in the name 
Zoledronic acid Hospira 
EMA/639412/2021 
Page 2/10 
 
 
 
 
 
 
 
 
 
 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
PSUSA/3149/
Periodic Safety Update EU Single assessment - 
17/04/2020 
n/a 
PRAC Recommendation - maintenance 
201908 
zoledronic acid (indicated for cancer and fractures) 
N/0039 
Minor change in labelling or package leaflet not 
02/12/2019 
12/02/2020 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0038 
A.7 - Administrative change - Deletion of 
16/05/2019 
n/a 
manufacturing sites 
PSUSA/3149/
Periodic Safety Update EU Single assessment - 
11/04/2019 
n/a 
PRAC Recommendation - maintenance 
201808 
zoledronic acid (indicated for cancer and fractures) 
Zoledronic acid Hospira 
EMA/639412/2021 
Page 3/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/0037 
Minor change in labelling or package leaflet not 
09/04/2019 
12/02/2020 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0036 
A.7 - Administrative change - Deletion of 
05/02/2019 
12/02/2020 
Annex II and 
manufacturing sites 
N/0034 
Minor change in labelling or package leaflet not 
24/10/2018 
12/02/2020 
connected with the SPC (Art. 61.3 Notification) 
PL 
PL 
T/0033 
Transfer of Marketing Authorisation 
06/08/2018 
20/09/2018 
SmPC, 
Labelling and 
PL 
PSUSA/3149/
Periodic Safety Update EU Single assessment - 
12/04/2018 
n/a 
PRAC Recommendation - maintenance 
201708 
zoledronic acid (indicated for cancer and fractures) 
IB/0032 
B.II.e.4.c - Change in shape or dimensions of the 
21/03/2018 
n/a 
container or closure (immediate packaging) - Sterile 
medicinal products 
IAIN/0031/G 
This was an application for a group of variations. 
12/02/2018 
20/09/2018 
Annex II and 
PL 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Zoledronic acid Hospira 
EMA/639412/2021 
Page 4/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0030 
B.II.b.2.c.1 - Change to importer, batch release 
07/12/2017 
20/09/2018 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
N/0028 
Minor change in labelling or package leaflet not 
13/11/2017 
20/09/2018 
PL 
connected with the SPC (Art. 61.3 Notification) 
R/0026 
Renewal of the marketing authorisation. 
22/06/2017 
24/08/2017 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Zoledronic acid Hospira in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IB/0027/G 
This was an application for a group of variations. 
10/08/2017 
n/a 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.d.1.c - Stability of AS - Change in the re-test 
period/storage period or storage conditions - Change 
to an approved stability protocol 
PSUSA/3149/
Periodic Safety Update EU Single assessment - 
21/04/2017 
16/06/2017 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
201608 
zoledronic acid (indicated for cancer and fractures) 
the variation to terms of the Marketing Authorisation(s)’ for 
Zoledronic acid Hospira 
EMA/639412/2021 
Page 5/10 
 
 
 
 
 
 
 
 
 
 
 
 
N/0025 
Minor change in labelling or package leaflet not 
16/02/2017 
16/06/2017 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
IB/0023 
C.I.2.a - Change in the SPC, Labelling or PL of a 
19/08/2016 
16/06/2017 
SmPC and PL 
PSUSA/3149/201608. 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
N/0022 
Update of the package leaflet with revised contact 
17/06/2016 
16/06/2017 
PL 
details of the local representatives for Belgium, 
Germany, Spain, Ireland, Luxembourg, the 
Netherlands, Austria and Portugal. 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
IG/0693 
B.II.b.1.a - Replacement or addition of a 
02/06/2016 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IG/0645 
C.I.8.a - Introduction of or changes to a summary of 
17/12/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IAIN/0019/G 
This was an application for a group of variations. 
10/12/2015 
24/06/2016 
SmPC, 
A.1 - Administrative change - Change in the name 
Labelling and 
PL 
Zoledronic acid Hospira 
EMA/639412/2021 
Page 6/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
and/or address of the MAH 
C.I.3.a - Change(s) in the SPC, Labelling or PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Implementation of 
wording agreed by the competent authority 
IB/0018 
C.I.2.a - Change in the SPC, Labelling or PL of a 
27/10/2015 
24/06/2016 
Annex II 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0017/G 
This was an application for a group of variations. 
01/07/2015 
24/06/2016 
SmPC, Annex 
II and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IG/0555 
C.I.8.a - Introduction of or changes to a summary of 
22/05/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
Zoledronic acid Hospira 
EMA/639412/2021 
Page 7/10 
 
 
 
 
 
 
 
 
 
 
 
PSMF location 
IB/0015 
C.I.2.a - Change in the SPC, Labelling or PL of a 
19/12/2014 
11/02/2015 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0014/G 
This was an application for a group of variations. 
12/12/2014 
n/a 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
IG/0477 
C.I.8.a - Introduction of or changes to a summary of 
03/09/2014 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IB/0012 
C.I.2.a - Change in the SPC, Labelling or PL of a 
25/07/2014 
11/02/2015 
SmPC 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Zoledronic acid Hospira 
EMA/639412/2021 
Page 8/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/3149/
Periodic Safety Update EU Single assessment - 
10/04/2014 
n/a 
PRAC Recommendation - maintenance 
201308 
zoledronic acid (indicated for cancer and fractures) 
IB/0010 
C.I.2.a - Change in the SPC, Labelling or PL of a 
01/04/2014 
11/02/2015 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IG/0382 
C.I.8.a - Introduction of or changes to a summary of 
02/12/2013 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IB/0008/G 
This was an application for a group of variations. 
21/11/2013 
31/01/2014 
SmPC, Annex 
Update of SmPC section 4.4 Special warnings and 
II and PL 
precautions for 5mg/100 ml strength as requested by the 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.6.b - Change(s) to therapeutic indication(s) - 
Deletion of a therapeutic indication 
CHMP further to assessment of Aclasta PSUR 9 to include 
observation of acute renal failure after a single 
administration, and to advise calculation of creatinine 
clearance based upon actual body weight using the 
Cockroft -Gault formula prior to each dose. Deletion of 
reference to osteoporosis indication in SmPC section 4.1, 
4.2 and 5.1 and PL sections 1 and 3 due to the patent 
situation and as per legal advice. 
Accordingly update of physician educational material, also 
reflecting increased risk in subjects of advanced age. 
IAIN/0007 
B.II.b.1.a - Replacement or addition of a 
03/09/2013 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
Zoledronic acid Hospira 
EMA/639412/2021 
Page 9/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IG/0317 
C.I.z - Changes (Safety/Efficacy) of Human and 
23/07/2013 
n/a 
Veterinary Medicinal Products - Other variation 
IB/0004 
C.I.2.a - Change in the SPC, Labelling or PL of a 
16/07/2013 
31/01/2014 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
II and PL 
IAIN/0006 
B.II.b.1.a - Replacement or addition of a 
12/07/2013 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0003 
B.II.b.1.a - Replacement or addition of a 
13/05/2013 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0001 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
19/04/2013 
31/01/2014 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IG/0286 
C.I.z - Changes (Safety/Efficacy) of Human and 
12/04/2013 
n/a 
Veterinary Medicinal Products - Other variation 
Zoledronic acid Hospira 
EMA/639412/2021 
Page 10/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
